Long-Term Response to Sunitinib Therapy for Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer - United States
doi 10.1016/j.clgc.2013.04.001
Full Text
Abstract

Available in full text

Categories
OncologyUrology
Date
Authors
Publisher

Elsevier BV

Related search

Metastatic Clear Cell Renal Cell Carcinoma With a Long-Term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression

Clinical Genitourinary Cancer
OncologyUrology
2019English

Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

Therapeutic Advances in Urology
Urology
2016English

Brain Complete Response to Cabozantinib Prior to Radiation Therapy in Metastatic Renal Cell Carcinoma

Case Reports in Urology
2019English

Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination Combined With Sunitinib for Metastatic Renal Cell Carcinoma

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2014English

Hypertension as Predictor of Sunitinib Treatment Outcome in Metastatic Renal Cell Carcinoma

Acta Oncologica
Nuclear MedicineRadiologyHematologyOncologyMedicineImaging
2011English

Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma

Clinical Genitourinary Cancer
OncologyUrology
2015English

Improved Long-Term Clinical Outcomes and Safety Profile of Sunitinib Dosing Schedule With 4/2 Switched to 2/1 in Patients With Metastatic Renal Cell Carcinoma

Journal of Cancer
Oncology
2018English

Pneumatosis Cystoides Intestinalis Linked to Sunitinib Treatment for Renal Cell Carcinoma

IJU Case Reports
2019English

Molecular Subtyping of Metastatic Renal Cell Carcinoma: Implications for Targeted Therapy

Molecular Cancer
Cancer ResearchOncologyMolecular Medicine
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy